Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Ipamorelin peptide icon, one bubble per amino acidIpamorelin5 residues (approx.)AHXFKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

Ipamorelin

Beginner tier: 100 mcg, daily · 12w on / 4w off · community consensus

2 h half-life·Injection

Also known as: NNC 26-0161, Ipamorelin

Raun and colleagues tested ipamorelin at 200 times the effective growth hormone dose and still found zero cortisol or ACTH elevation [1]. That result made it the first selective growth hormone secretagogue. The pentapeptide triggers a clean GH pulse through the ghrelin receptor (GHS-R1a). In swine, it did not raise prolactin or stress hormones [1], and users report little hunger. No human efficacy trial has succeeded yet; the only published Phase 2 RCT missed its endpoint, and a second never posted results. Still, hundreds of r/peptides threads and a 4.5/5 community sentiment score put ipamorelin in the top five most-discussed peptides. Adults looking for GH optimization with the fewest hormonal side effects start here, usually stacked with CJC-1295 (no DAC).

What Is Ipamorelin?

Zero cortisol increase at 200 times the effective GH dose. That single data point from Raun et al. (1998)[1] explains why ipamorelin became the default starter peptide for growth hormone optimization.

Ipamorelin (molecular weight ~711 Da) is a synthetic pentapeptide and selective GHS-R1a agonist. It binds the ghrelin receptor on pituitary somatotroph cells, producing a GH pulse within 15 to 30 minutes of subcutaneous injection. Gobburu and colleagues gave healthy men 15-minute IV infusions and modeled the result (1999)[2]. They measured a 2-hour half-life and one GH peak at about 40 minutes.

The real-world use case is straightforward. Most users inject 100 to 300 mcg subcutaneously, one to three times daily on an empty stomach. Nearly everyone stacks it with CJC-1295 (no DAC), also called Mod GRF 1-29, to hit both GHS-R1a and GHRH receptor pathways simultaneously. That dual-pathway approach produces a GH pulse two to three times larger than either peptide alone. Bedtime dosing is the priority; the fasting window matters because insulin raises somatostatin, which fully blunts the GH response.

Community evidence is strong. Hundreds of r/peptides threads (roughly 95,000 subscribers) consistently report improved sleep within one to two weeks, faster recovery by weeks three to four, and gradual body composition changes over six to twelve weeks. The scientific picture is less complete. The only published human RCT, a Phase 2 trial in 117 adults after bowel resection, missed its key endpoint versus placebo (Beck 2014)[6]. A second, 320-patient Phase 2 trial (NCT01280344) finished in 2014 without posted results or a paper. All efficacy data for anti-aging and body composition applications is community-derived. Preclinical work on bone mineral content (Svensson et al. 2000)[3] and cachexia (2024 ferret model)[4] looks promising but hasn't been replicated in humans.

How Ipamorelin Works

Ipamorelin binds selectively to the growth hormone secretagogue receptor type 1a (GHS-R1a) on anterior pituitary somatotroph cells. This receptor is the same target ghrelin activates. Ipamorelin was developed for selective GH release, and users report far less hunger than on GHRP-6. In mice, ipamorelin raised body fat, and secretagogue treatment raised food intake (Lall et al. 2001)[8].

Once GHS-R1a activates, it triggers intracellular calcium signaling in somatotrophs, prompting GH vesicle release into circulation. In healthy men given 15-minute IV infusions, the GH pulse peaked at about 40 minutes (Gobburu et al. 1999)[2]. That pulse then stimulates hepatic IGF-1 production, the downstream mediator of most growth hormone effects on tissue repair, lipolysis, and protein synthesis.

The selectivity is what sets ipamorelin apart. GHRP-2 and GHRP-6 both activate GHS-R1a but also stimulate ACTH release, cortisol secretion, and prolactin elevation at therapeutic doses. Raun et al. (1998)[1] demonstrated that ipamorelin produced no measurable cortisol or ACTH increase even at doses 200 times above the GH-effective threshold. This means it can be dosed multiple times daily without accumulating stress hormone burden.

The 2-hour half-life [2] allows for a pulsatile dosing pattern that mimics natural GH secretion rhythms rather than creating the sustained tonic GH elevation seen with CJC-1295 (with DAC). Pairing ipamorelin with CJC-1295 (no DAC) hits both the GHS-R1a and GHRH receptor simultaneously, producing a complementary pulse roughly two to three times larger than either alone.

Ipamorelin Benefits

  • Ipamorelin benefits center on clean growth hormone optimization with the lowest side-effect burden of any GHRP available.
  • No cortisol or prolactin elevation in swine. Raun et al. found no prolactin rise, and no ACTH or cortisol rise even at more than 200 times the GH-releasing dose [1].
  • Improved deep sleep quality within one to two weeks of starting, the most consistently first-reported benefit across hundreds of r/peptides threads.
  • Exposure rose in step with dose across five IV infusion levels in healthy men, and the half-life held at 2 hours [2].
  • Less hunger than GHRP-6, by user reports, which suits fat-loss goals. No human study has measured hunger on it. In mice, it raised body fat (Lall et al. 2001)[8].
  • Bone mineral content improvements documented in rodent models at 12-plus weeks of dosing (Svensson et al. 2000; Andersen et al. 2001)[3][5], with the compound also countering glucocorticoid-induced bone loss.
  • No receptor desensitization documented with continuous use, unlike hexarelin. The 12-on/4-off cycling protocol is precautionary rather than evidence-based for ipamorelin specifically.

Ipamorelin: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 9 key studies·Research only

Mechanism well-established: selective GHS-R1a agonist producing a clean GH pulse without cortisol, ACTH, or prolactin co-activation in swine (Raun et al. 1998)[1].

Dosing studied: 100–300 mcg per injection (community-derived); 1–3 injections per day (no clinical trial established an optimal frequency)
Read the evidence (key study, limitations)

Human PK-PD used 15-minute IV infusions in healthy men (Gobburu et al. 1999)[2]. It found a ~2h half-life, dose-proportional kinetics and one GH peak at ~40 min. The only published human RCT (Phase 2, postoperative ileus after bowel resection, n=117; Beck 2014)[6] showed no efficacy vs. placebo; a second Phase 2 trial (NCT01280344, n=320, completed 2014) never posted results. Ipamorelin has never passed a positive human efficacy trial. No new human RCTs published 2024–2026; new 2024 animal data [4] supports cachexia application but is preclinical only.

Key Study

Raun et al. 1998 (PMID 9849822): established ipamorelin as first selective GHS; no cortisol/ACTH elevation even at 200× the effective GH dose. Gobburu et al. 1999 (PMID 10496658): human PK-PD modeling after 15-minute IV infusions in healthy men; 2h half-life, dose-proportional PK, GH peak at ~40 min.

Limitations

Only published human RCT (Phase 2, postoperative ileus after bowel resection, PMID 25331030) missed its key endpoint; a second Phase 2 trial (NCT01280344) never posted results. No approved clinical indication. All long-term dosing and efficacy data is community-derived. Preclinical findings (bone, fat) not replicated in a human trial. New 2024 cachexia study (PMID 39043357) is ferret model only.

Community Experience
Strong
4.5/5
Based on hundreds of r/Peptides threads

Widely regarded as the safest and most beginner-friendly GHRP.

Community dosing: 100–300 mcg per injection, 1–3× daily; most common: 200 mcg ipamorelin + 100 mcg CJC-1295 (no DAC), 1–2× daily
Read the reports (what users report 5, common issues 5)

"Cleanest GHRP": no cortisol, prolactin, or appetite spike vs. GHRP-2 and GHRP-6. Almost universally stacked with CJC-1295 (no DAC) rather than used solo. Primary uses: GH optimization, sleep quality, body recomposition, recovery.

What users report (5)
  • No cortisol, prolactin, or appetite increase: safest side-effect profile among all GHRPs
  • Improved deep sleep quality within 1–2 weeks (most consistent first-reported effect)
  • Faster workout recovery by weeks 3–4
  • Gradual lean body composition improvement and fat loss over 6–12 weeks
  • No receptor desensitization documented with continuous use (unlike hexarelin)
Common issues (5)
  • Slow onset: visible body composition changes require 6–12 weeks; common expectation mismatch
  • Strict 2-hour fasting window before injection: compliance is the most common failure point
  • Mild injection-site redness/irritation (transient)
  • Transient post-injection headache resolving within hours
  • Product quality variable: DAC/no-DAC mislabeling, underdosing, and degradation documented
Partially Aligned

Science and community agree on GHS-R1a mechanism, selectivity vs. other GHRPs, GH pulse characteristics, and 2h half-life. Community dosing of 100–300 mcg/injection aligns with published PK-PD dose-response data. Key divergence: the only published human RCT (postoperative ileus, Phase 2) failed vs. placebo, while community consistently reports sleep and body composition benefits from off-label use. Community applications differ from the failed clinical indication. Fasting window requirement is mechanistically sound (insulin→somatostatin→blunted GH pulse).

Ipamorelin Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDose / InjectionFrequency
Beginner100 mcg
DailyTrack
Moderate200 mcg
2x DailyTrack
Aggressive300 mcg
3x DailyTrack
Note:

With a 2 mg vial and 2 mL bacteriostatic water, you'll get 1,000 mcg/mL. Each 100 mcg dose is 10 units on an insulin syringe. A 5 mg vial reconstituted with 2 mL gives 2,500 mcg/mL, so 200 mcg is 8 units and 300 mcg is 12 units per injection.

The fasting window is the thing most beginners mess up. You need at least two hours with no food before injection. Insulin triggers somatostatin release, which completely blocks the GH pulse. Eating within that window isn't "suboptimal"; it negates the injection entirely. No food for 30 minutes after, either.

Bedtime dosing is priority number one. It amplifies the natural nocturnal GH pulse. If you're dosing twice daily, the morning shot should be fasted on waking. Space injections at least eight hours apart.

Store lyophilized vials at 2 to 8 degrees Celsius. After reconstitution, keep refrigerated and use within three to four weeks. Toss anything cloudy or with particles floating in it.

If you see zero sleep improvement after two weeks with correct fasting timing, suspect the product before blaming the protocol. Get an IGF-1 lab at week four to confirm the peptide is actually working. Product quality varies significantly.

Cycling Protocol

On Period
12 weeks
Off Period
4 weeks

Cycle to maintain receptor sensitivity. Can also be run 5 days on, 2 off weekly.

Calculate your Ipamorelin dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Ipamorelin Protocols by Goal

beginnerCommunity12 weeks on, 4 weeks off
Induction
Wk 1–2
100 mcg · Once daily (bedtime) · Subcutaneous
Maintenance
Wk 3–12
100 mcg · Once daily (bedtime) · Subcutaneous

Expected: Improved sleep quality weeks 1–2; recovery improvement weeks 3–4; modest body composition changes by months 2–3

Monitor: Baseline IGF-1 before starting; recheck at week 6 and week 12. Fasting glucose at baseline.

Who Uses Ipamorelin?

Ben Greenfield
Ben Greenfield

Biohacker & Bestselling Author

Reviewed

I have personally seen the best results using Ipamorelin before bedtime on an empty stomach.

300 mcg custom-days · subcutaneousWolverine Stack
Ben GreenfieldDr. Craig KoniverJay CampbellJoe RoganHunter Williams
+1
Ben Greenfield, Dr. Craig Koniver, Jay Campbell and 3 more
have published Ipamorelin protocols with dosing

How to Use Ipamorelin

  1. 1
    Reconstitute the vial

    Pull bacteriostatic water into an insulin syringe (29 to 31 gauge). For a 2 mg vial, add 2 mL BAC water to get 1,000 mcg per mL. For a 5 mg vial, add 2 mL to get 2,500 mcg per mL. Let the water slide down the glass wall of the vial. Never spray directly onto the lyophilized powder. Swirl gently until dissolved.

  2. 2
    Calculate your syringe units

    At 1,000 mcg/mL (2 mg vial + 2 mL): 100 mcg = 10 units, 200 mcg = 20 units, 300 mcg = 30 units. At 2,500 mcg/mL (5 mg vial + 2 mL): 100 mcg = 4 units, 200 mcg = 8 units, 300 mcg = 12 units.

  3. 3
    Confirm fasting

    At least two hours since your last meal. No exceptions, the GH pulse is fully blunted by insulin.

  4. 4
    Clean the injection site with an alcohol swab

    Abdomen (avoiding the navel area) is preferred. Rotate sites with each injection.

  5. 5
    Step 5

    Pinch the skin, insert the needle at a 45-degree angle, inject slowly, and hold for five seconds before withdrawing.

  6. 6
    Step 6

    If stacking with CJC-1295 (no DAC), draw both peptides into the same syringe or inject at the same site sequentially. Co-administration at the same time is standard.

  7. 7
    No food for 30 minutes post-injection

    Store the reconstituted vial in the refrigerator immediately.

Timing: bedtime is the priority injection (30 to 60 minutes before sleep). If dosing twice daily, add an AM fasted injection on waking. If three times daily, add a post-workout fasted injection spaced at least three hours from other doses.

Alternative Routes

Intranasal

No human study has measured intranasal or subcutaneous bioavailability. In male rats, intranasal bioavailability was about 20% (PMID 9879640). No dose conversion is established.

Not used in practice due to low and variable mucosal absorption. No standardized intranasal protocol exists in community or clinical settings. SC injection remains the only practical route.

Mixing your own vial? Use the Ipamorelin reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Ipamorelin Stacking Protocols

Works With

Avoid

GHRP-6

Concurrent use of two GHRPs causes receptor competition at GHS-R1a with no additional GH benefit. GHRP-6's intense hunger and ghrelin-pathway activation defeats the primary reason to choose ipamorelin (less hunger than GHRP-6, by user reports). Stack one GHRP only.

GHRP-2

Competing GHRPs at the same GHS-R1a receptor: no additive GH benefit documented. GHRP-2 adds cortisol and prolactin co-elevation that ipamorelin specifically avoids. Defeats the rationale for choosing ipamorelin. Choose one GHRP per stack.

CJC-1295 (with DAC)

DAC version's days-long half-life creates sustained tonic GH stimulation that mismatches ipamorelin's pulsatile mechanism. Suppresses natural nocturnal GH peaks and pituitary pulsatility over time. Use CJC-1295 no-DAC (Mod GRF 1-29) instead.

Exogenous HGH (recombinant GH / somatropin)

Combining GH secretagogues with exogenous HGH saturates the GH axis, suppresses endogenous pulsatility, and eliminates the primary rationale for secretagogue use (axis preservation). Dramatically increases IGF-1 overshoot and side-effect risk.

Do not combine

How much does Ipamorelin cost?

Typical price

$4.46 to $6.47 per mg

Typical $5.50

Middle half of 94 US prices for 10 mg vials · read Oct 31

See prices

Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.

Compounded
Not on the 503A bulks list (21 CFR 216.23); FDA's compounding advisory committee voted against adding it on Oct 29, 2024. Telehealth/anti-aging clinic pricing for ipamorelin or CJC+Ipa combo (with physician oversight, labs, prescription): ~$200–$600/month.

Pricing updated 2026-04-09

Ipamorelin Side Effects

The most serious risk with ipamorelin is IGF-1 overshoot. Sustained supraphysiological IGF-1 levels carry a theoretical cancer promotion risk, particularly in anyone with active malignancy or a history of cancer. GH promotes cell proliferation. That's the mechanism behind its benefits and its biggest concern. If IGF-1 climbs above the age-adjusted upper normal range on two consecutive readings, the protocol should stop.

Carpal tunnel symptoms (tingling or numbness in the hands) are the clearest signal that GH levels have gone too high. Community reports flag this primarily at the aggressive tier (300 mcg three times daily). This isn't a "push through it" side effect. Tingling means stop immediately, wait at least four weeks, and restart at a lower dose and frequency if appropriate.

Water retention is common, especially at twice-daily or three-times-daily dosing. Mild puffiness around the face or ankles is the typical presentation. Reducing injection frequency (not dose) is the first adjustment.

Transient headache within 30 to 60 minutes of injection is expected and relates directly to the acute GH pulse. It resolves within hours for most users. Cutting the dose by 25% usually handles persistent headache.

Injection-site reactions (mild redness, irritation) are reported frequently in the first two weeks and tend to resolve with consistent site rotation. Abdomen is the preferred injection location.

Occasional lightheadedness immediately post-injection is reported but typically mild.

Published side effect data in humans is limited. Only one human RCT has been published (Phase 2, 117 adults after bowel resection)[6]. It used intravenous dosing and tracked adverse events, but its endpoints were GI recovery, not the subcutaneous anti-aging use case. A second Phase 2 trial in 320 bowel-resection patients (NCT01280344) finished in 2014 and never posted results. Community side-effect reporting across hundreds of threads is remarkably consistent, which provides reasonable confidence in the profile above, but formal incidence rates don't exist for the off-label application.

GH release antagonizes insulin action. Fasting glucose should be monitored at baseline, week six, and week twelve. Anyone with uncontrolled diabetes or severe insulin resistance should not use ipamorelin. A fasting glucose above 126 mg/dL means discontinuation.

Pregnancy and breastfeeding are contraindicated due to insufficient safety data. GH supplementation can also unmask subclinical hypothyroidism by accelerating T4-to-T3 conversion; thyroid monitoring (TSH, fT3) is recommended at baseline.

When to see a doctor: persistent hand tingling or numbness, significant edema, fasting glucose above 126 mg/dL, any visual changes, or symptoms of intracranial hypertension.

Common Issues & Solutions

No IGF-1 change after 6–8 weeks: most common cause is eating within 2 hours before injection: insulin raises somatostatin and fully blunts the GH pulse. Verify fasting compliance before blaming product quality. Then a batch-specific CoA can rule out underdosing or degradation.

Transient headache within 30–60 min of injection: expected with acute GH release; resolves within hours. Reduce dose by 25% if severe or lasting. Ensure adequate hydration pre-injection.

Water retention or hand tingling: reduce injection frequency first (not dose). Tingling/numbness in hands = early carpal tunnel sign: stop immediately and allow 4+ weeks recovery before restarting at lower dose.

Results much slower than expected: ipamorelin is not an acute performance compound: visible body composition changes require 6–12 weeks minimum. Common error is comparing onset timeline to anabolic steroids. IGF-1 lab confirmation at week 4–6 can confirm the protocol is working before visible changes appear.

Suspected product quality issue: CJC-1295 DAC/no-DAC mislabeling is common in lower-quality products. If stacking and seeing no sleep improvement in week 1–2 despite correct timing, suspect product substitution. A CoA specifying ipamorelin molecular weight (~711 Da) is the only way to confirm identity.

Ask AI about this page

Ask AI for a second opinion on Ipamorelin dosing and side effects

Contraindications

  • Active malignancy or history of cancer (GH may promote tumor growth)
  • Pregnancy or breastfeeding (insufficient safety data)
  • Uncontrolled diabetes or severe insulin resistance
  • Intracranial hypertension or active pituitary tumors
  • Known hypersensitivity to ipamorelin or any excipients
  • Children with closed epiphyseal plates (no benefit; risk of side effects)

Drug Interactions

  • Exogenous growth hormone (HGH): concurrent use may cause supraphysiological GH levels and increased side effects
  • Glucocorticoids (prednisone, dexamethasone): may blunt GH release and reduce ipamorelin efficacy
  • Insulin: combined GH elevation can impair glucose tolerance; monitor blood sugar closely
  • Somatostatin analogs (octreotide): directly oppose GH release and will negate ipamorelin effects
  • Concurrent use of two GHRPs causes receptor competition at GHS-R1a with no additional GH benefit. GHRP-6's intense hunger and ghrelin-pathway activation defeats the primary reason to choose ipamorelin (less hunger than GHRP-6, by user reports). Stack one GHRP only.
  • Competing GHRPs at the same GHS-R1a receptor: no additive GH benefit documented. GHRP-2 adds cortisol and prolactin co-elevation that ipamorelin specifically avoids. Defeats the rationale for choosing ipamorelin. Choose one GHRP per stack.

Product Quality

Recommended Monitoring

TestWhenTarget
IGF-1Baseline before starting; repeat at week 6 and week 12Age-adjusted normal range (not supraphysiological). Flag if consistently above upper limit of normal.
IGFBP-3Baseline; repeat at week 12Age-adjusted normal range
Fasting glucoseBaseline; repeat at week 6 and week 12<100 mg/dL (normal); 100–125 mg/dL warrants dose reduction and closer monitoring; >126 mg/dL = discontinue
Thyroid (TSH, fT3)Baseline; repeat at week 12 if symptoms emergeNot listed
IGF-1

Primary efficacy marker for GH axis activation. Confirms peptide is working and dosing is adequate. Elevated IGF-1 above age-adjusted upper normal indicates dose reduction needed.

IGFBP-3

Low IGFBP-3 with elevated IGF-1 increases free (bioactive) IGF-1 fraction and downstream cancer signaling risk. IGF-1 alone is insufficient for safe GH axis monitoring.

Fasting glucose

GH release antagonizes insulin action. Relevant for pre-diabetic or insulin-resistant individuals. Risk is lower than with exogenous HGH but warrants monitoring at higher doses.

Thyroid (TSH, fT3)

GH accelerates T4-to-T3 conversion. Untreated hypothyroidism blunts GH response to ipamorelin. GH supplementation can unmask subclinical hypothyroidism.

Ipamorelin Before and After

Weeks 1-2

Improved sleep quality and deeper sleep onset. Mild injection-site reactions may occur. GH pulses begin but effects are not yet visible.

Weeks 3-4

Noticeable improvements in recovery after exercise. Subtle skin and energy changes. GH and IGF-1 levels begin to rise measurably.

Weeks 5-8

Fat loss becomes apparent, especially around the midsection. Recovery time shortens. Joint and soft-tissue comfort may improve.

Weeks 9-12

Peak benefits in body composition, sleep quality, and recovery. Skin elasticity and tone improvements reported. IGF-1 levels stabilize at elevated baseline.

Weeks 13-16
off-cycle

Receptor sensitivity reset period. Retain most gains from the cycle. GH and IGF-1 gradually return toward pre-cycle baseline over 2-4 weeks.

What to Expect

Weeks 1 to 2: GH pulse augmentation starts with the first injection. In Gobburu's IV infusion study in healthy men [2], GH peaked at about 40 minutes. Sleep quality is the first thing most users notice, often within the first week or two. Deeper sleep onset and more vivid dreams show up consistently across community reports. Mild injection-site redness is common and resolves within hours. Some users report lightheadedness right after the shot. Transient headache in the first 30 to 60 minutes is expected from the acute GH release.

Weeks 3 to 4: IGF-1 becomes measurably raised around week four. Recovery after training improves noticeably, with reduced DOMS and faster bounce-back between sessions. Subtle skin texture and hydration changes start showing up. Some users spot early lean tissue fullness and a bump in daily energy. Mild water retention is possible at twice-daily dosing frequency.

Weeks 5 to 8: Fat loss becomes visible, particularly around the midsection. Recovery windows keep shrinking. Joint and soft-tissue comfort improvements get mentioned frequently in this phase. Skin elasticity changes are noticeable for some users. Rodent studies at this duration showed bone mineral content improvements (Svensson et al. 2000)[3], though human data for this endpoint doesn't exist yet.

Weeks 9 to 12: Peak cycle window. Body composition results are at their best here, with fat loss and muscle fullness peaking. Sleep quality holds steady. Some users report diminishing returns around weeks 10 to 12 and choose to end the cycle early. At the aggressive tier (300 mcg three times daily), mild carpal tunnel-like symptoms are possible. Water retention is the most common nuisance at this stage.

Weeks 13 to 16 (off-cycle): Ipamorelin's short half-life (roughly 2 hours) means it clears the system within 10 to 12 hours of the last injection, no prolonged GH bleed. Pituitary GHS-R1a receptor sensitivity recovers within two to four weeks off. Most users retain a solid portion of their cycle gains for four to six weeks post-cycle. GH and IGF-1 drift back toward pre-cycle baseline gradually. No crash or acute withdrawal has been reported.

Detailed Timeline: Science vs Community

Weeks 1–2
Science

GH pulse augmentation begins with first injection. Human PK-PD (Gobburu 1999, IV infusion) found a GH peak at ~40 min. IGF-1 elevation detectable within days of consistent dosing.

Community

Improved deep sleep quality and more vivid dreams are the first-reported effects, often within 1–2 weeks. Mild injection-site redness resolving within hours. Occasional lightheadedness immediately post-injection.

Weeks 3–4
Science

IGF-1 measurably elevated at week 4 (consistent with GH axis studies). GH promotes anabolic signaling in connective tissue and muscle protein synthesis.

Community

Faster workout recovery, reduced DOMS, subtle improvements in skin texture and hydration. Some users notice early lean tissue fullness and improved energy.

Weeks 5–8
Science

Sustained GH/IGF-1 elevation drives lipolysis and anabolic signaling. Bone mineral content improvements shown at 12+ weeks in rodent models (Svensson et al. 2000, PMID 10828840).

Community

Fat loss begins to show, particularly midsection. Recovery time shortens noticeably. Joint and soft-tissue comfort improvements reported. Skin elasticity improvements noted by some users.

Weeks 9–12
Science

GH and IGF-1 plateau at sustained elevated baseline. Bone mineral content progressively improves with continued dosing per rodent data. No desensitization documented in ipamorelin-specific literature.

Community

Best body composition results of the cycle: fat loss and muscle fullness peak. Sleep quality sustained. Some users experience diminishing returns by weeks 10–12 and end cycle early.

Weeks 13–16 (off-cycle)
Science

Short half-life (~2h) means ipamorelin clears within 10–12h of last injection (no prolonged GH bleed). Pituitary GHS-R1a receptor sensitivity should recover within 2–4 weeks off.

Community

Most users retain a significant portion of cycle gains for 4–6 weeks post-cycle. GH and IGF-1 gradually return toward pre-cycle baseline over 2–4 weeks. No crash or acute withdrawal reported.

Pharmacokinetics

Half-Life
2h
Bioavailability
SC: not measured in humans; intranasal ~20% in male rats (PMID 9879640)
Tmax
0.25-0.5 hours
Data Confidence
high

Source: PK-PD modeling in human volunteers (Pharm Res 1999, PMID 10496658)

Pharmacokinetics: Active Dose Over Time

t½ = ~2 hours

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
5
Molecular Weight
711.85 Da
Sequence
AHXFK
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Ipamorelin

  • Adults seeking natural growth hormone optimization with less hunger than GHRP-6 (user reports)
  • Beginners to GH peptide therapy looking for the mildest side-effect profile
  • Athletes and active adults focused on recovery and lean body composition
  • Older adults with age-related GH decline seeking improved sleep and recovery
  • Individuals stacking with CJC-1295 (No DAC) for pulsatile GH release

Related Peptides

What Changed for Ipamorelin

  1. Evidence

    Corrected Oct 15, 2026: ipamorelin's only published human RCT is Beck 2014; a second, 320-patient Phase 2 trial ended without results, per ClinicalTrials.gov.

    Before: The only completed human RCT (Phase 2b, postoperative ileus, approximately 100 participants) After: The only published human RCT (Phase 2, 117 adults after bowel resection, PMID 25331030); a second Phase 2 trial (NCT01280344, 320 patients) finished in 2014 without posted results

    What this does not mean: Both trials gave ipamorelin intravenously after bowel surgery; neither tested subcutaneous use. Dose tiers on this page are unchanged.

    Source: ClinicalTrials.gov NCT01280344, Phase 2 dose-finding trial of ipamorelin vs. placebo for GI recovery after bowel resection (320 enrolled, completed May 2014, no results posted; last update posted Apr 13, 2017) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations

References

  1. [1]Ipamorelin, the first selective growth hormone secretagogue (Eur J Endocrinol 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers (Pharm Res 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]The GH secretagogues ipamorelin and GHRP-6 increase bone mineral content in adult female rats (J Endocrinol 2000) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets (Lu et al., Physiol Behav 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]The GH secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats (Growth Horm IGF Res 2001) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (Beck et al., Int J Colorectal Dis 2014) (opens in a new tab)(n=117)PubMed (opens in a new tab)PubMed
  7. [7]Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption (Johansen et al., Xenobiotica 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
  8. [8]Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues (Lall et al., Biochem Biophys Res Commun 2001) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Resources

Related Tools

Storage & Stability

Before Reconstitution
Refrigerate at 2-8°C, stable up to 12 months
After Reconstitution
Refrigerate, use within 3-4 weeks
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

Without DAC, also called Mod GRF 1-29. The DAC version creates a sustained GH "bleed" instead of a pulse, which doesn't match ipamorelin's pulsatile mechanism and can blunt your natural GH rhythm over time. The no-DAC version has an estimated ~30-minute half-life and should be injected simultaneously with ipamorelin 2-3x daily. Some clinics sell pre-mixed blends.

Sleep quality usually improves first, often within 1-2 weeks. Recovery improvements show up at weeks 3-4. Visible body composition changes (fat loss, muscle fullness) take 6-8 weeks minimum of consistent use. IGF-1 lab changes are measurable at 4 weeks. This is a slow-burn compound, not an acute performance drug.

Unlike hexarelin, ipamorelin doesn't cause receptor desensitization with continuous use. The standard 12-on/4-off cycle is precautionary, not evidence-based for ipamorelin specifically. A 2-year study showed no pituitary suppression with a related GHS. Some longevity clinics run it continuously with monitoring.

Both bind the same ghrelin receptor (GHS-R1a), so the difference rests mostly on user reports. Community reports describe strong hunger about 20 minutes after GHRP-6 and little or none on ipamorelin. Raun et al. 1998 (PMID 9849822) is often credited with this, but that swine study did not measure appetite. It measured hormones: ipamorelin raised GH without raising ACTH or cortisol, while GHRP-6 and GHRP-2 raised both.

Different receptor pathways entirely. Sermorelin is a GHRH analog (acts on GHRH receptors); ipamorelin is a GHRP (acts on GHS-R1a). Sermorelin produces a more physiological GH pulse. Community reports call ipamorelin's pulse faster and stronger per dose; no human study has tested that ranking. For best results, stack both or combine ipamorelin with Mod GRF 1-29 to hit both pathways. If picking just one, community reports favor ipamorelin.